Literature DB >> 25722197

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Anne F Luetkemeyer1, Susan L Rosenkranz2, Darlene Lu2, Beatriz Grinsztejn3, Jorge Sanchez4, Michael Ssemmanda5, Ian Sanne6, Helen McIlleron7, Diane V Havlir1, David W Haas8.   

Abstract

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV/AIDS; efavirenz; pharmacogenetic; rifampin; tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 25722197      PMCID： PMC4542662          DOI： 10.1093/cid/civ155

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  19 in total

1.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Authors:  Diane V Havlir; Michelle A Kendall; Prudence Ive; Johnstone Kumwenda; Susan Swindells; Sarojini S Qasba; Anne F Luetkemeyer; Evelyn Hogg; James F Rooney; Xingye Wu; Mina C Hosseinipour; Umesh Lalloo; Valdilea G Veloso; Fatuma F Some; N Kumarasamy; Nesri Padayatchi; Breno R Santos; Stewart Reid; James Hakim; Lerato Mohapi; Peter Mugyenyi; Jorge Sanchez; Javier R Lama; Jean W Pape; Alejandro Sanchez; Aida Asmelash; Evans Moko; Fred Sawe; Janet Andersen; Ian Sanne
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

2.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Authors:  François-Xavier Blanc; Thim Sok; Didier Laureillard; Laurence Borand; Claire Rekacewicz; Eric Nerrienet; Yoann Madec; Olivier Marcy; Sarin Chan; Narom Prak; Chindamony Kim; Khemarin Kim Lak; Chanroeurn Hak; Bunnet Dim; Chhun Im Sin; Sath Sun; Bertrand Guillard; Borann Sar; Sirenda Vong; Marcelo Fernandez; Lawrence Fox; Jean-François Delfraissy; Anne E Goldfeld
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

Review 3.  Clinical impact of patient population differences and genomic variation in efavirenz therapy.

Authors:  Jennifer King; Judith A Aberg
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

4.  The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Authors:  Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

5.  Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

Authors:  Anne F Luetkemeyer; Susan L Rosenkranz; Darlene Lu; Florence Marzan; Prudence Ive; Evelyn Hogg; Susan Swindells; Constance A Benson; Beatriz Grinsztejn; Ian M Sanne; Diane V Havlir; Francesca Aweeka
Journal:  Clin Infect Dis       Date:  2013-04-16       Impact factor: 9.079

6.  Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Authors:  Kelly E Dooley; Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; David W Haas; Jennifer Hull; Regina Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron
Journal:  J Infect Dis       Date:  2014-07-31       Impact factor: 5.226

7.  Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Authors:  David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court
Journal:  J Antimicrob Chemother       Date:  2014-04-11       Impact factor: 5.790

8.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Authors:  Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-12       Impact factor: 2.089

9.  Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.

Authors:  Helen M McIlleron; Michael Schomaker; Yuan Ren; Phumla Sinxadi; James J C Nuttall; Hermien Gous; Harry Moultrie; Brian Eley; Concepta Merry; Peter Smith; David W Haas; Gary Maartens
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

10.  Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

Authors:  Julie Bertrand; Céline Verstuyft; Monidarin Chou; Laurence Borand; Phalla Chea; Kuy Huong Nay; François-Xavier Blanc; France Mentré; Anne-Marie Taburet
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226
View more
  14 in total

1.  Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Authors:  Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton
Journal:  Tuberculosis (Edinb)       Date:  2018-10-01       Impact factor: 3.131

2.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Authors:  Daniel Atwine; Maryline Bonnet; Anne-Marie Taburet
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

Review 3.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

4.  Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.

Authors:  Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Janet W Andersen; Thando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Peter Kim; Courtney V Fletcher
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

5.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

6.  Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.

Authors:  Paul Leger; Sanika Chirwa; Megan Turner; Danielle M Richardson; Paxton Baker; Michael Leonard; Husamettin Erdem; Lana Olson; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2016-10       Impact factor: 2.089

7.  Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.

Authors:  David W Haas; Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Paxton Baker; Courtney V Fletcher
Journal:  Pharmacogenet Genomics       Date:  2021-01       Impact factor: 2.000

8.  Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.

Authors:  Adriana Weinberg; Lisa Aaron; Grace Montepiedra; Timothy R Sterling; Renee Browning; Blandina Mmbaga; Tichaona Vhembo; Shilpa Naik; Enid Kabugho; Gaerolwe Masheto; Savita Pahwa; Jyoti S Mathad; Sylvia M LaCourse; Katie McCarthy; Sarah Bradford; Gerhard Theron; Diane Costello; Bonnie Zimmer; Marie F Pierre; Kamunkhwala Gausi; Paolo Denti; David W Haas; Amita Gupta
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

Review 9.  Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.

Authors:  Laurent Abel; Jacques Fellay; David W Haas; Erwin Schurr; Geetha Srikrishna; Michael Urbanowski; Nimisha Chaturvedi; Sudha Srinivasan; Daniel H Johnson; William R Bishai
Journal:  Lancet Infect Dis       Date:  2017-10-27       Impact factor: 25.071

10.  Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.

Authors:  David W Haas; Rosie Mngqibisa; Jose Francis; Helen McIlleron; Jennifer A Robinson; Michelle A Kendall; Paxton Baker; Sajeeda Mawlana; Sharlaa Badal-Faesen; Francis Angira; Ayotunde Omoz-Oarhe; Wadzanai P Samaneka; Paolo Denti; Susan E Cohn
Journal:  Pharmacogenet Genomics       Date:  2022-01-01       Impact factor: 2.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.